Rhonda Hellums - 02 Jan 2025 Form 3 Insider Report for Silence Therapeutics plc (SLN)

Role: Chief Financial Officer
Signature: /s/ Rhonda Hellums
Issuer symbol: SLN
Transactions as of: 02 Jan 2025
Net transactions value: $0
Form type: 3
Filing time: 02 Jan 2025, 16:32:09 UTC
Next filing: 06 Jan 2026
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SLN	Ordinary Shares						1,500	02 Jan 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SLN	Employee Share Option (Right to Buy)							02 Jan 2025	Ordinary Shares	75,000	$8.14	Direct	F1
holding	SLN	Employee Share Option (Right to Buy)							02 Jan 2025	Ordinary Shares	55,998	$7.87	Direct	F2
holding	SLN	Employee Share Option (Right to Buy)							02 Jan 2025	Ordinary Shares	150,000	$6.33	Direct	F3
holding	SLN	Employee Share Option (Right to Buy)							02 Jan 2025	Ordinary Shares	375,000	$3.86	Direct	F4
holding	SLN	Employee Share Option (Right to Buy)							02 Jan 2025	Ordinary Shares	600,000	$5.13	Direct	F5
holding	SLN	Employee Share Option (Right to Buy)							02 Jan 2025	Ordinary Shares	79,506	$3.33	Direct	F6
holding	SLN	Employee Share Option (Right to Buy)							02 Jan 2025	Ordinary Shares	238,518	$5.90	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One fourth (1/4th) of the shares subject to the option vested on April 29, 2022 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.
F2	This option vested or shall vest in equal monthly installments over a four-year period measured from one month following January 6, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
F3	This option vested or shall vest in equal monthly installments over a four-year period measured from one month following February 21, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
F4	This option vested or shall vest in equal monthly installments over a five-year period measured from one month following September 16, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
F5	This option vested or shall vest in equal monthly installments over a four-year period measured from one month following January 5, 2023, subject to the Reporting Person's continuous service as of the applicable vesting date.
F6	One fourth (1/4th) of the shares subject to the option vested on September 14, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.
F7	One fourth (1/4th) of the shares subject to the option shall vest on January 4, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.